Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes

被引:6
作者
Dinoto, Alessandro [1 ]
Sartori, Arianna [1 ]
Cheli, Marta [1 ]
Pasquin, Fulvio [1 ]
Baldini, Sara [1 ]
Bratina, Alessio [1 ]
Bosco, Antonio [1 ]
Manganotti, Paolo [1 ]
机构
[1] Univ Trieste, Cattinara Univ Hosp, Dept Med Surg & Hlth Sci, Neurol Unit, Str Fiume 447, I-34149 Trieste, Italy
关键词
Multiple sclerosis; Dimethyl fumarate; Lymphopenia; Disease modifying drugs; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;
D O I
10.1016/j.msard.2021.103357
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Lymphopenia is a common side effect of treatment with dimethyl fumarate (DMF) in patients with multiple sclerosis (PwMS). Prevalence and predictive factors of this side effect are still uncertain, because literature has provided discrepant results and it is still a matter of debate if lymphopenia is associated with a better treatment outcome.Methods: We retrospectively recruited PwMS treated for at least one month with DMF and collected clinical, demographic data and absolute lymphocyte count (ALC) during follow-up. Lymphopenia was graded according to CTCAE. Patients according to the grade in lymphopenia (all grades) and severe lymphopenia (grade II-IV). To evaluate predictors of lymphopenia, we compared characteristics of patients with/without lymphopenia and patients with/without severe lymphopenia. A logistic binary regression was performed to elucidate any predictive factor of lymphopenia and severe lymphopenia. Area under the curve (AUC) was calculated to evaluate sensibility and specificity of predictors. We analyzed treatment outcome with NEDA-3 status at 1-and 2-years.Results: 98 of 105 patients treated with DMF were included. 46.9% developed lymphopenia, 27.6% severe lymphopenia. Lymphopenia was associated with basal ALC (p < 0.001, AUC=0.786), treatment duration (p = 0.01, AUC=0.685),% of reduction at third month (p = 0.001, AUC=0.616) Severe lymphopenia was associated with basal ALC (p = 0.003, AUC=0.750).NEDA-3 status at 1-year (n = 66) and at 2-year (n = 44) did not differ in patients with/without lymphopenia (p = 0.059; p = 0.583) or with/without severe lymphopenia (p = 1.02; p = 0.169).Conclusion: Lymphopenia is a common side effect of DMF and basal ALC predicts its development. Lymphopenia is not associated with the achievement of NEDA-3 status.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
    Ozel, Osman
    Vaughn, Caila B.
    Eckert, Svetlana P.
    Jakimovski, Dejan
    Lizarraga, Alexis A.
    Weinstock-Guttman, Bianca
    PATIENT-RELATED OUTCOME MEASURES, 2019, 10 : 373 - 384
  • [32] Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
    Longbrake, Erin E.
    Ramsbottom, Michael J.
    Cantoni, Claudia
    Ghezzi, Laura
    Cross, Anne H.
    Piccio, Laura
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (08) : 1061 - 1070
  • [33] Liver injury associated with dimethyl fumarate in multiple sclerosis patients
    Munoz, Monica A.
    Kulick, Corrinne G.
    Kortepeter, Cindy M.
    Levin, Robert L.
    Avigan, Mark I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1947 - 1949
  • [34] Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis
    Hosseini, Arezoo
    Masjedi, Ali
    Baradaran, Behzad
    Hojjat-Farsangi, Mohammad
    Ghalamfarsa, Ghasem
    Anvari, Enayat
    Jadidi-Niaragh, Farhad
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (07) : 9943 - 9955
  • [35] Dimethyl fumarate treatment alters NK cell function in multiple sclerosis
    Smith, Matthew D.
    Calabresi, Peter A.
    Bhargava, Pavan
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 48 (02) : 380 - 383
  • [36] Cryptococcal meningitis in a patient with multiple sclerosis on dimethyl fumarate treatment: A case
    Workel, H. H.
    Wolfhagen, M. J. H. M.
    Bouwhuis, J. W.
    Kloosterziel, M. E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 42
  • [37] Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate
    Jozef, Maj
    Locatelli, Igor
    Jakob, Gregor Brecl
    Rot, Uros
    Kos, Mitja
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 72
  • [38] Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment
    Garbo, Riccardo
    Lorenzut, Simone
    Del Negro, Ilaria
    Merlino, Giovanni
    Gigli, Gian Luigi
    Cargnelutti, Daniela
    Valente, Mariarosaria
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 49
  • [39] Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient
    Perini, Paola
    Rinaldi, Francesca
    Puthenparampil, Marco
    Marcon, Michela
    Perini, Francesco
    Gallo, Paolo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 26 : 68 - 70
  • [40] Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
    Buckle, Guy
    Bandari, Daniel
    Greenstein, Jeffrey
    Gudesblatt, Mark
    Khatri, Bhupendra
    Kita, Mariko
    Repovic, Pavle
    Riser, Emily
    Weinstock-Guttman, Bianca
    Thrower, Ben
    Loring, Sherrill
    Riester, Katherine
    Everage, Nick
    Prada, Claudia
    Koulinska, Irene
    Mann, Monica
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (02)